Drug repurposing using high-throughput screening identifies a promising drug combination to treat adrenocortical carcinoma

Lerário, Antônio Marcondes; Hammer, Gary D.

doi:10.18632/oncotarget.26091

Cited by 2 publications

(1 citation statement)

References 11 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Promptly developing computational approached merging different “-omics” and multi-network multi-layered data sets, will facilitate future repurposing of drugs for multiple oncological indications. As already demonstrated [ 230 , 231 ], repurposing drugs in combination with other agents could potentially improve clinical outcomes in cancer patients.…”

Section: Discussionmentioning

confidence: 81%

Drug repurposing in oncology: Compounds, pathways, phenotypes and computational approaches for colorectal cancer

Nowak-Śliwińska

Scapozza

Altaba

2019

Biochimica et Biophysica Acta (BBA) - Reviews on Cancer

142

View full text Add to dashboard Cite

The strategy of using existing drugs originally developed for one disease to treat other indications has found success across medical fields. Such drug repurposing promises faster access of drugs to patients while reducing costs in the long and difficult process of drug development. However, the number of existing drugs and diseases, together with the heterogeneity of patients and diseases, notably including cancers, can make repurposing time consuming and inefficient. The key question we address is how to efficiently repurpose an existing drug to treat a given indication. As drug efficacy remains the main bottleneck for overall success, we discuss the need for machine-learning computational methods in combination with specific phenotypic studies along with mechanistic studies, chemical genetics and omics assays to successfully predict disease-drug pairs. Such a pipeline could be particularly important to cancer patients who face heterogeneous, recurrent and metastatic disease and need fast and personalized treatments. Here we focus on drug repurposing for colorectal cancer and describe selected therapeutics already repositioned for its prevention and/or treatment as well as potential candidates. We consider this review as a selective compilation of approaches and methodologies, and argue how, taken together, they could bring drug repurposing to the next level.

show abstract

Section: Discussionmentioning

confidence: 81%